Abstract
Napabucasin (also known as BBI-608 or BBI608) is an investigational, oral agent hypothesized to inhibit multiple oncogenic pathways. In this article, we describe the design and rationale for the CanStem111P clinical trial, a multicenter, randomized, open-label, Phase III study designed to determine the efficacy and safety of combining napabucasin with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma (NCT02993731). Patients were randomized in a 1:1 fashion to receive weekly gemcitabine and nab-paclitaxel with or without napabucasin. The results of this study will help define the role of this novel agent in the management of advanced pancreatic cancer.
Original language | English |
---|---|
Pages (from-to) | 1295-1302 |
Number of pages | 8 |
Journal | Future Oncology |
Volume | 15 |
Issue number | 12 |
DOIs | |
Publication status | Published - Apr 2019 |
Keywords
- BBI-608
- cancer stem cells
- CanStem111P
- napabucasin
- pancreatic adenocarcinoma
ASJC Scopus subject areas
- Oncology
- Cancer Research